AU2004226369A1 - Compositions and methods involving respiratory syncytial virus subgroup B strain 9320 - Google Patents

Compositions and methods involving respiratory syncytial virus subgroup B strain 9320 Download PDF

Info

Publication number
AU2004226369A1
AU2004226369A1 AU2004226369A AU2004226369A AU2004226369A1 AU 2004226369 A1 AU2004226369 A1 AU 2004226369A1 AU 2004226369 A AU2004226369 A AU 2004226369A AU 2004226369 A AU2004226369 A AU 2004226369A AU 2004226369 A1 AU2004226369 A1 AU 2004226369A1
Authority
AU
Australia
Prior art keywords
seq
leu
amino acid
nucleic acid
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004226369A
Other languages
English (en)
Inventor
Xing Cheng
Hong Jin
Hyun Jung Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2004226369A1 publication Critical patent/AU2004226369A1/en
Assigned to MEDIMMUNE, LLC reassignment MEDIMMUNE, LLC Alteration of Name(s) of Applicant(s) under S113 Assignors: MEDIMMUNE VACCINES, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027Paramyxoviridae, e.g. respiratory syncytial virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2004226369A 2003-03-28 2004-03-26 Compositions and methods involving respiratory syncytial virus subgroup B strain 9320 Abandoned AU2004226369A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45833103P 2003-03-28 2003-03-28
US60/458,331 2003-03-28
US50832003P 2003-10-03 2003-10-03
US60/508,320 2003-10-03
PCT/US2004/009438 WO2004087062A2 (en) 2003-03-28 2004-03-26 Compositions and methods involving respiratory syncytial virus subgroup b strain 9320

Publications (1)

Publication Number Publication Date
AU2004226369A1 true AU2004226369A1 (en) 2004-10-14

Family

ID=33135096

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004226369A Abandoned AU2004226369A1 (en) 2003-03-28 2004-03-26 Compositions and methods involving respiratory syncytial virus subgroup B strain 9320

Country Status (8)

Country Link
US (3) US7572904B2 (enExample)
EP (1) EP1613345B1 (enExample)
JP (1) JP4783726B2 (enExample)
AT (1) ATE469170T1 (enExample)
AU (1) AU2004226369A1 (enExample)
CA (1) CA2520671C (enExample)
DE (1) DE602004027362D1 (enExample)
WO (1) WO2004087062A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531491A (ja) * 2002-09-27 2007-11-08 メディミューン・ヴァクシンズ・インコーポレーテッド 呼吸器合胞体ウイルスにおける機能的突然変異
AU2004226369A1 (en) * 2003-03-28 2004-10-14 Medimmune, Llc Compositions and methods involving respiratory syncytial virus subgroup B strain 9320
FR2885139B1 (fr) 2005-04-29 2010-12-24 Agronomique Inst Nat Rech Preparation de complexes solubles proteine n-proteine p tronquee ou de proteine n soluble d'un virus de la famille des paramyxoviridae et leurs utilisations vaccinales
WO2007093050A1 (en) * 2006-02-13 2007-08-23 Olga Ornatsky Gene expression assays conducted by elemental analysis
AU2007222798A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
FR2899902B1 (fr) * 2006-04-18 2012-01-27 Agronomique Inst Nat Rech Proteines de fusion proteine n d'un virus de la famille des paramyxoviridae-proteine d'interet et leurs utilisations pour la vaccination et la vectorisation intra-cellulaire.
CN101679513A (zh) * 2007-03-06 2010-03-24 西福根有限公司 用于治疗呼吸道合胞病毒感染的重组抗体
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
US8354230B2 (en) 2007-12-21 2013-01-15 Quest Diagnostics Investments Inc. Multiplex detection assay for influenza and RSV viruses
AU2009311287C1 (en) * 2008-11-05 2015-02-19 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus
GB201019240D0 (en) 2010-11-15 2010-12-29 Vib Vzw Respiratory syncytical virus vaccine
US10227569B2 (en) * 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
ES2854673T3 (es) 2013-03-14 2021-09-22 Univ Emory VSR recombinante con mutaciones silenciosas, vacunas y métodos relacionados con ello
WO2017075125A1 (en) 2015-10-29 2017-05-04 Emory University Chimeric RSV, Immunogenic Compositions, and Methods of Use
US12102671B2 (en) 2015-11-04 2024-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of vaccination with an attenuated RSV vaccine formulation
AU2023349013A1 (en) * 2022-09-29 2025-04-17 Beijing Benewill Technology Development Co., Ltd. Respiratory syncytial virus recombinant fusion protein with prefusion conformation, and preparation method therefor and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800078A (en) 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
EP0932684A2 (en) * 1996-09-27 1999-08-04 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
US6017694A (en) * 1997-12-19 2000-01-25 American Cyanamid Company Methods of screening for modulators of respiratory syncytial virus matrix protein interaction
JP2002507408A (ja) * 1998-03-26 2002-03-12 アメリカン・サイアナミド・カンパニー 麻疹ウイルスもしくはヒト呼吸合胞体ウイルスサブグループbの弱毒化の原因である突然変異
CA2430115C (en) 2000-11-28 2013-02-26 Aviron, Inc. Recombinant rsv virus expression systems and vaccines
DK1351981T3 (da) * 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
JP2007531491A (ja) 2002-09-27 2007-11-08 メディミューン・ヴァクシンズ・インコーポレーテッド 呼吸器合胞体ウイルスにおける機能的突然変異
AU2004226369A1 (en) * 2003-03-28 2004-10-14 Medimmune, Llc Compositions and methods involving respiratory syncytial virus subgroup B strain 9320

Also Published As

Publication number Publication date
EP1613345B1 (en) 2010-05-26
WO2004087062A3 (en) 2005-03-31
JP2006524053A (ja) 2006-10-26
US20040224309A1 (en) 2004-11-11
EP1613345A2 (en) 2006-01-11
WO2004087062A2 (en) 2004-10-14
DE602004027362D1 (de) 2010-07-08
CA2520671A1 (en) 2004-10-14
US20120263744A1 (en) 2012-10-18
EP1613345A4 (en) 2007-01-10
US20090285853A1 (en) 2009-11-19
ATE469170T1 (de) 2010-06-15
JP4783726B2 (ja) 2011-09-28
US7572904B2 (en) 2009-08-11
US8163530B2 (en) 2012-04-24
CA2520671C (en) 2014-03-18

Similar Documents

Publication Publication Date Title
US8163530B2 (en) Nucleic acids encoding respiratory syncytial virus subgroup B strain 9320
US5993824A (en) Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
JP5743794B2 (ja) 生弱毒化呼吸器合胞体ウイルス
CA2302867A1 (en) Attenuated respiratory syncytial viruses
US6689367B1 (en) Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
KR100746979B1 (ko) 클로닝된 뉴클레오티드 서열로부터의 약독화된 키메릭호흡기 신시티움 바이러스 백신의 제조
JP2011250798A5 (enExample)
US6830748B1 (en) Recombinant RSV virus expression systems and vaccines
US9119812B2 (en) Influenza hemagglutinin and neuraminidase variants
AU2016366771B2 (en) Recombinant respiratory syncytial virus strains with mutations in the M2-2 ORF providing a range of attenuation phenotypes
KR20230021115A (ko) 생 약독화된 호흡기 세포융합 바이러스 (live attenuated respiratory syncytial virus)
AU5592201A (en) Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
AU5591601A (en) Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application